Orthocell has today published its Quarterly Report for the period ended 31 March 2022. Standout achievements for this Quarter include: Remplir™ nerve repair device receives Australian regulatory approval for introduction into the Australian nerve repair and regeneration market Application for inclusion of Remplir™ on the Prostheses List on track for submission in Q2 CY2022 Final […]
Orthocell CEO and Managing Director Paul Anderson spoke with Andrew Scott from Proactive Investors about passing a key milestone in the OrthoATI™ rotator cuff tendon study.
Orthocell’s Remplir™ device has gained Australian regulatory (Therapeutics Goods Administration) approval.
Orthocell’s Striate+™ dental membrane, which facilitates high quality and efficient bone and tissue repair, is gaining commercial momentum.
On International Day of Women In Science, we’re proud to shine a spotlight on Orthocell’s Quality Director, Monique Cannon.
Orthocell (ASX $OCC) has today published its Quarterly Report for the period ended 31 December 2021.
Orthocell (ASX $OCC) MD, Paul Anderson, was interviewed by Matt Birney on the Bulls N’ Bears Report about our latest OrthoATI™ clinical data.
Orthocell (ASX $OCC) has been featured in The West Australian in a story titled, “Orthocell’s tendon injury treatment a game-changer, clinical trial finds”, following the release of positive clinical data for our OrthoATI™ cell therapy last week.
Orthocell (ASX $OCC) has today released positive clinical data for its OrthoATI™ tendon program, which shows that OrthoATI™ is statistically more effective than the current standard of care (corticosteroid injection) for treatment of rotator cuff tendinopathy with intrasubstance tendon tear.
Orthocell (ASX $OCC) has today released an update on its Ortho-ATI™ rotator cuff tendon study – the database is now locked and the Company is track to report the highly anticipated top line results in Q4 this calendar year. This study was designed to assess the effectiveness of Ortho-ATI™, compared to corticosteroids, as a non-surgical […]